drugset / Trial / NCT04510233
Ivermectin Nasal Spray for COVID19 Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The global escalation of COVID19 pandemic has put the health care system under pressure with urgent need for treatment. In the absence of vaccine and approved drug against SARS-COV2 over the past 6 months, the health authorities were obliged to re-purpose existing drugs to fight this pandemic.
Timeline
- Start
- 2020-09
- Primary completion
- 2020-10
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivermectin | Small molecule | 1 ml | Intranasal |
| Subject | Ivermectin | Small molecule | 6 mg | Intranasal |